Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsHye Won Lee, Carolyn S.P. Lam, Shun Kohsaka et al.|Journal of the American College of Cardiology|2018Cited by 465
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD studyJohan Sundström, Navdeep Tangri, Tiago Taveira‐Gomes et al.|The Lancet Regional Health - Europe|2022Cited by 315
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Dianna J. Magliano, Matthias Saathoff et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93